Octreotide Nanoparticles Showed Affinity for In Vivo MIA Paca-2 Inducted Pancreas Ductal Adenocarcinoma Mimicking Pancreatic Polypeptide-Secreting Tumor of the Distal Pancreas (PPoma).

Autor: Braga TL; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil., Pinto SR; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil., Dos Reis SRR; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil., Portilho FL; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil., da Silva de Barros AO; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil., Bernardes ES; Centro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares, São Paulo, Brazil., Dos Santos SN; Centro de Radiofarmácia, Instituto de Pesquisas Energéticas e Nucleares, São Paulo, Brazil., Alencar LMR; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil.; Department of Physics, Federal University of Maranhão, São Luís, Maranhão, Brazil., Ricci-Junior E; Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Santos-Oliveira R; Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, Rio de Janeiro, Brazil. presidenciaradiofarmacia@gmail.com.; Laboratory of Radiopharmacy and Nano-radiopharmaceuticals, Zona Oeste State University, Rio de Janeiro, Brazil. presidenciaradiofarmacia@gmail.com.
Jazyk: angličtina
Zdroj: Pharmaceutical research [Pharm Res] 2019 Aug 05; Vol. 36 (10), pp. 143. Date of Electronic Publication: 2019 Aug 05.
DOI: 10.1007/s11095-019-2678-4
Abstrakt: Purpose: Pancreatic Polypeptide-secreting tumor of the distal pancreas (PPoma) is a rare, difficult and indolent type of cancer with a survival rate of 5-year in only 10% of all cases. The PPoma is classified as a neuroendocrine tumor (NET) not functioning that overexpresses SSTR 2 (somatostatin receptor subtype 2). Thus, in order to improve the diagnosis of this type of tumor, we developed nanoparticulate drug carriers based on poly-lactic acid (PLA) polymer loaded with octreotide and radiolabeled with Technetium-99 m ( 99m Tc).
Methods: PLA/PVA octreotide nanoparticles were developed by double-emulsion technique. These nanoparticles were characterized by Atomic Force Microscopy (AFM) and Dynamic Light Scattering (DLS) and radiolabeled with 99mTc by the direct via forming 99m Tc-PLA/PVA octreotide nanoparticles. The safety of these nanosystems was evaluated by the MTT cell toxicity assay and their in vivo biodistribution was evaluated in xenografted inducted animals.
Results: The results showed that a 189 nm sized nanoparticle were formed with a PDI of 0,097, corroborating the monodispersive behavior. These nanoparticles were successfully radiolabeled with 99mTc showing uptake by the inducted tumor. The MTT assay corroborated the safety of the nanosystem for the cells.
Conclusion: The results support the use of this nanosystem ( 99m Tc-PLA/PVA octreotide nanoparticles) as imaging agent for PPoma. Graphical Abstract Polypeptide-Secreting Tumor of the Distal Pancreas (PPoma) Radiolabeled Nanoparticles for Imaging.
Databáze: MEDLINE
Externí odkaz: